After IPO, BridgeBio Looks To Tuck Eidos Back Into Its Flock

Is Eidos a goose that could lay a golden egg? BridgeBio wants to own it all, instead of two-thirds, in case its subsidiary's lead program in TTR amyloidosis succeeds in Phase III.

Eggs_Nest
In case Eidos's ATTR drug AG10 is a golden egg, BridgeBio wants to own it all. • Source: Shutterstock

BridgeBio Pharma Inc. launched the largest initial public offering so far this year by a biopharmaceutical company in the US and, now that the IPO has closed, it's looking to increase the return on its investment in one of its subsidiary companies – Eidos Therapeutics Inc.

Palo Alto, CA-based BridgeBio's business model is to find intriguing genetic disease drug candidates and spin out subsidiaries around each...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

IPO Update: With Just Two Small Offerings In Q2, What’s Next?

 
• By 

With low valuations for biopharma companies that recently went public and little hope of a near-term turnaround as uncertainty lingers, IPO numbers may stay low for the rest of 2025.

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

Novartis Upbeat Even With Entresto Expiry Looming

 
• By 

Swiss major confident that new oncology drugs will fill revenue gap.